Related Experiment Video
Updated: Jul 30, 2026

09:51
One Minute, Sub-One-Watt Photothermal Tumor Ablation Using Porphysomes, Intrinsic Multifunctional Nanovesicles
Published on: September 17, 2013
Laparoscopic partial nephrectomy using the potassium titanyl phosphate laser in a porcine model
R G Hindley1, N J Barber, K Walsh
1King's College Hospital, London, United Kingdom. richard.hindley@virgin.net
Urology
|April 26, 2006
Summary
Laparoscopic partial nephrectomy using the potassium titanyl phosphate (KTP) Greenlight laser is feasible in pigs. This novel technique offers excellent hemostasis with minimal blood loss, paving the way for human trials.
Area of Science:
- Urology
- Minimally Invasive Surgery
- Laser Technology
Background:
- Evaluating the efficacy of the potassium titanyl phosphate (KTP) Greenlight laser for partial nephrectomy.
- Assessing the feasibility of KTP laser partial nephrectomy in a porcine model.
Purpose of the Study:
- To determine the potential and feasibility of using the KTP Greenlight laser for laparoscopic partial nephrectomy.
- To establish a porcine model for evaluating this novel surgical technique.
Main Methods:
- 15 laparoscopic partial nephrectomies performed in 4 pigs under anesthesia.
- Utilized an 80-W KTP laser for bilateral upper and lower pole nephrectomies without renal cooling or vessel clamping.
- Monitored blood loss, operating time, and smoke formation; performed histopathologic analysis of specimens.
Main Results:
- Successful completion of all procedures with minimal estimated blood loss (<30 mL).
- Mean operating time of 42 minutes; only one instance required additional hemostasis.
- Histopathology revealed minimal changes at the resection line (<1 mm).
- Smoke formation intermittently reduced visibility during the procedure.
Conclusions:
- Demonstrated the feasibility and efficacy of KTP laser partial nephrectomy in a normally perfused porcine model.
- The KTP laser provides excellent renal parenchymal hemostatic ablation.
- Ongoing efforts focus on mitigating smoke formation to enhance visibility for future human clinical trials.

